Thousands of people who face life-threatening blood diseases, such as leukemia, lymphoma and multiple myeloma, require treatment with a stem cell transplantation (also referred to as a bone marrow transplantation). For many patients, the best treatment approach is an allogeneic transplant, in which healthy stem cells are collected from another person. The stem cell donor is selected based on how well his or her Human Leukocyte Antigen (HLA) markers match that of the patient. Although a person’s HLA type is inherited from his or her parents, the likelihood of finding an HLA match with a family member is only 25 …
As 2013 comes to a close, we’re looking back at some of our favorite Insight posts from the last year. From inspiring patient stories to important research, here is our top 10 list:
Stem cell transplantation (sometimes called bone marrow transplants) is a treatment for certain forms of cancer, such as leukemia, lymphoma, and multiple myeloma, as well as other diseases. But before a patient can receive a transplant, stem cells must be collected from a donor (an allogeneic donation) or from the patient (an autologous transplant).
Cancer or blood disorder patients may have central lines, which make it easier to receive certain medications (such as chemotherapy) and have blood tests. The major types of central lines include Port-A-Cath, Hickman, and peripherally inserted central catheter (PICC). Patients receiving stem cell transplants sometimes have central lines. If you have a central line, you may need to care for it at home. Or you may need guidance in caring for a loved one with a central line. Knowing the correct procedures is essential to preventing infection.
By Catherine MacLean “Why is this coming up now?” “It’s been 10 years. I should be over this already.” “Why is this happening to me? All of the other survivors I know seem fine.” These thoughts preoccupied me during the transition from high school to college. It had been 10 years since my successful bone marrow transplant for aplastic anemia and my health was excellent.
by Martha Laperle When my son Ryan ran the Boston Marathon this year, I watched him with a special level of pride. Not only had he completed his first-ever marathon in four hours, but he was running, in large part, because of me. Just over a year earlier, at the age of 57, I had been diagnosed with an aggressive form of acute myeloid leukemia (AML), a diagnosis that turned my life upside down and led to weeks of chemotherapy and a stem cell transplant at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC). Ryan was running to raise funds for the …
By Christine Cleary The 21st century has seen great strides in treatment for multiple myeloma, a cancer of the bone marrow once considered a death sentence. In fact, thanks to research by Dana-Farber scientists, this blood cancer that took the lives of Geraldine Ferraro and Leonard P. Zakim has become a chronic disease for many patients.
By Saul Wisnia Wendy Akeson is passionate about both running and donating platelets. Never has she felt such a strong connection between these two roles as she did this year. Four minutes after completing her 10th consecutive Boston Marathon, Akeson heard the explosions that will forever link this year’s marathon with tragedy – and then saw people running toward her from the finish line she had just crossed.
By Maria Pearson As a technology teacher who had a long career with IBM before going into education, I have encountered all sorts of opportunities to teach – and to learn. The biggest such opportunity of my life occurred at the intersection of cancer, technology, and Dana-Farber. In August 2010, I was diagnosed with stage III multiple myeloma, a blood cancer. No search engine was adequate in comforting my fears of life expectancy, treatment, or facing a stark life-altering challenge.